{"id":1209,"date":"2025-11-10T20:00:57","date_gmt":"2025-11-10T20:00:57","guid":{"rendered":"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/"},"modified":"2026-09-07T18:50:35","modified_gmt":"2026-09-07T18:50:35","slug":"slu-pp-332-vs-o-304-exercise-mimetic-comparison","status":"publish","type":"post","link":"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/","title":{"rendered":"SLU-PP-332 vs O-304: Exercise Mimetic Comparison"},"content":{"rendered":"<div class=\"ez-toc-v2_0_81 counter-hierarchy ez-toc-counter ez-toc-light-blue ez-toc-container-direction\" id=\"ez-toc-container\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<p><span class=\"ez-toc-title-toggle\"><a aria-label=\"Toggle Table of Content\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" href=\"#\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg class=\"list-377408\" fill=\"none\" height=\"20px\" style=\"fill: #999;color:#999\" viewbox=\"0 0 24 24\" width=\"20px\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg baseprofile=\"tiny\" class=\"arrow-unsorted-368013\" height=\"10px\" style=\"fill: #999;color:#999\" version=\"1.2\" viewbox=\"0 0 24 24\" width=\"10px\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"><\/path><\/svg><\/span><\/span><\/span><\/a><\/span><\/p><\/div>\n<nav>\n<ul class=\"ez-toc-list ez-toc-list-level-1\">\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#SLU-PP-332_vs_O-304_Exercise_Mimetic_Comparison\">SLU-PP-332 vs O-304: Exercise Mimetic Comparison<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#SLU-PP-332_and_O-304_Introduction\">SLU-PP-332 and O-304 Introduction<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Molecular_Structure_and_Chemical_Data_Comparison\">Molecular Structure and Chemical Data Comparison<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#SLU-PP-332_vs_O-304_Research_Areas\">SLU-PP-332 vs O-304 Research Areas<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Mechanism_of_Action_SLU-PP-332_vs_O-304\">Mechanism of Action: SLU-PP-332 vs O-304<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Clinical_Research_and_Study_Results_Comparison\">Clinical Research and Study Results Comparison<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Future_Research_Directions_for_Both_Compounds\">Future Research Directions for Both Compounds<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Availability_and_Access_SLU-PP-332_vs_O-304\">Availability and Access: SLU-PP-332 vs O-304<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Summary_and_Conclusion\">Summary and Conclusion<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#References\">References<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Molecular_Structure_and_Chemical_Data_Comparison-2\">Molecular Structure and Chemical Data Comparison<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#SLU-PP-332_vs_O-304_Research_Areas-2\">SLU-PP-332 vs O-304 Research Areas<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Mechanism_of_Action_SLU-PP-332_vs_O-304-2\">Mechanism of Action: SLU-PP-332 vs O-304<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-14\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Clinical_Research_and_Study_Results_Comparison-2\">Clinical Research and Study Results Comparison<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-15\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Future_Research_Directions_for_Both_Compounds-2\">Future Research Directions for Both Compounds<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-16\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Availability_and_Access_SLU-PP-332_vs_O-304-2\">Availability and Access: SLU-PP-332 vs O-304<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-17\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#Summary_and_Conclusion-2\">Summary and Conclusion<\/a><\/li>\n<li class=\"ez-toc-page-1 ez-toc-heading-level-2\"><a class=\"ez-toc-link ez-toc-heading-18\" href=\"https:\/\/lotilabs.com\/resources\/slu-pp-332-vs-o-304-exercise-mimetic-comparison\/#References-2\">References<\/a><\/li>\n<\/ul>\n<\/nav>\n<\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"SLU-PP-332_vs_O-304_Exercise_Mimetic_Comparison\"><\/span><span class=\"ez-toc-section\" id=\"SLU-PP-332_vs_O-304_Exercise_Mimetic_Comparison\"><\/span><span class=\"ez-toc-section\" id=\"SLU-PP-332_vs_O-304_Exercise_Mimetic_Comparison\"><\/span><span class=\"ez-toc-section\" id=\"SLU-PP-332_vs_O-304_Exercise_Mimetic_Comparison\"><\/span><a href=\"https:\/\/lotilabs.com\/buy\/slu-pp-332-liquid-25mg-per-ml\/\" rel=\"noopener noreferrer\" target=\"_self\">SLU-PP-332<\/a> vs O-304: Exercise Mimetic Comparison<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"SLU-PP-332_and_O-304_Introduction\"><\/span><span class=\"ez-toc-section\" id=\"SLU-PP-332_and_O-304_Introduction\"><\/span><span class=\"ez-toc-section\" id=\"SLU-PP-332_and_O-304_Introduction\"><\/span><span class=\"ez-toc-section\" id=\"SLU-PP-332_and_O-304_Introduction\"><\/span>SLU-PP-332 and O-304 Introduction<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>SLU-PP-332 works through <strong>estrogen related receptors<\/strong> activation, specifically ERR\u03b1, O-304 through AMPK activation pathways, but As of available research data, O-304 (also known as <strong>ATX-304<\/strong>, developed by Amplifier Therapeutics) has progressed to Phase IIa human clinical trials, while <strong>SLU-PP-332<\/strong> remains in preclinical research stages with no published human trial data.<\/p>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Molecular_Structure_and_Chemical_Data_Comparison\"><\/span><span class=\"ez-toc-section\" id=\"Molecular_Structure_and_Chemical_Data_Comparison\"><\/span><span class=\"ez-toc-section\" id=\"Molecular_Structure_and_Chemical_Data_Comparison\"><\/span><span class=\"ez-toc-section\" id=\"Molecular_Structure_and_Chemical_Data_Comparison\"><\/span>Molecular Structure and Chemical Data Comparison<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p><a href=\"https:\/\/lotilabs.com\/buy\/slu-pp-332-liquid-25mg-per-ml\/\" rel=\"noopener noreferrer\" target=\"_self\"><strong>SLU-PP-332<\/strong><\/a> is a small molecule <strong>synthetic ERR\u03b1<\/strong> agonist developed at <strong>Louis University<\/strong>, research published in <strong>ACS Chem Biol<\/strong> shows its potent activation of <strong>estrogen related receptors<\/strong>. The compound has good oral bioavailability, suitable for research use.<\/p>\n<p>O-304 (clinically designated <strong>ATX-304<\/strong> by its developer <strong>Amplifier Therapeutics<\/strong>) is a pan-AMPK activator with a characterized salt formulation. Both compounds target <strong>energy metabolism<\/strong> pathways but differ in chemical structure and upstream signaling: SLU-PP-332 acts at the transcription factor level (nuclear ERR activation), while O-304 works via enzyme signaling (cytoplasmic AMPK activation).<\/p>\n<p><a href=\"https:\/\/lotilabs.com\/buy\/slu-pp-332-liquid-25mg-per-ml\/\" rel=\"noopener noreferrer\" target=\"_self\"><strong>SLU-PP-332<\/strong><\/a> is stable under normal lab conditions and has consistent pharmacokinetic profile in preclinical studies.<\/p>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"SLU-PP-332_vs_O-304_Research_Areas\"><\/span><span class=\"ez-toc-section\" id=\"SLU-PP-332_vs_O-304_Research_Areas\"><\/span><span class=\"ez-toc-section\" id=\"SLU-PP-332_vs_O-304_Research_Areas\"><\/span><span class=\"ez-toc-section\" id=\"SLU-PP-332_vs_O-304_Research_Areas\"><\/span>SLU-PP-332 vs O-304 Research Areas<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p><strong>Cardiovascular Safety \u2014 Resting Heart Rate:<\/strong> Preclinical research in mice has identified a notable finding with SLU-PP-332: the compound produced a measurable increase in <strong>resting heart rate<\/strong>. This cardiovascular signal is considered a significant research variable for ERR agonists and represents an area requiring further investigation before human trial applications can be considered. No equivalent cardiovascular signal has been reported in O-304 (ATX-304) Phase IIa trial data.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_SLU-PP-332_vs_O-304\"><\/span><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_SLU-PP-332_vs_O-304\"><\/span><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_SLU-PP-332_vs_O-304\"><\/span><span class=\"ez-toc-section\" id=\"Mechanism_of_Action_SLU-PP-332_vs_O-304\"><\/span>Mechanism of Action: SLU-PP-332 vs O-304<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Clinical_Research_and_Study_Results_Comparison\"><\/span><span class=\"ez-toc-section\" id=\"Clinical_Research_and_Study_Results_Comparison\"><\/span><span class=\"ez-toc-section\" id=\"Clinical_Research_and_Study_Results_Comparison\"><\/span><span class=\"ez-toc-section\" id=\"Clinical_Research_and_Study_Results_Comparison\"><\/span>Clinical Research and Study Results Comparison<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Safety profile of <strong>slu pp 332<\/strong> looks good in preclinical studies with no significant adverse effects in <strong>mice<\/strong> models.<\/p>\n<p>O-304 research data is limited in the literature, more research is needed to establish efficacy and safety profiles.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Future_Research_Directions_for_Both_Compounds\"><\/span><span class=\"ez-toc-section\" id=\"Future_Research_Directions_for_Both_Compounds\"><\/span><span class=\"ez-toc-section\" id=\"Future_Research_Directions_for_Both_Compounds\"><\/span><span class=\"ez-toc-section\" id=\"Future_Research_Directions_for_Both_Compounds\"><\/span>Future Research Directions for Both Compounds<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>Combination therapy studies are emerging, particularly on how <strong>slu pp 332<\/strong> can complement existing <strong>diabetes<\/strong> treatments or lifestyle interventions. Long term effects on <strong>mitochondrial function<\/strong> and <strong>cellular respiration<\/strong> need to be investigated.<\/p>\n<p>Regulatory pathways for both compounds need to be considered as <strong>experimental therapeutics<\/strong>. The risk of misuse as performance-enhancing agents requires appropriate regulatory framework for clinical development and therapeutic use.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Availability_and_Access_SLU-PP-332_vs_O-304\"><\/span><span class=\"ez-toc-section\" id=\"Availability_and_Access_SLU-PP-332_vs_O-304\"><\/span><span class=\"ez-toc-section\" id=\"Availability_and_Access_SLU-PP-332_vs_O-304\"><\/span><span class=\"ez-toc-section\" id=\"Availability_and_Access_SLU-PP-332_vs_O-304\"><\/span>Availability and Access: SLU-PP-332 vs O-304<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<p>Both <strong>slu pp 332<\/strong> and O-304 are in research phase and not <strong>FDA approved<\/strong> for clinical use. Access is limited to research institutions and qualified investigators conducting research on <strong>exercise mimetics<\/strong> and <strong>metabolic<\/strong> health interventions.<\/p>\n<p><strong>SLU-PP-332<\/strong> is available through research peptide suppliers but requires quality verification and compliance with institutional research protocols. The compound is an investigational <strong>drug<\/strong> and requires proper oversight and adherence to research ethics guidelines.<\/p>\n\n<p>Cost for research use depends on compound complexity and synthesis requirements. As research progresses and manufacturing scales up, availability and cost may improve for qualified research applications.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Summary_and_Conclusion\"><\/span><span class=\"ez-toc-section\" id=\"Summary_and_Conclusion\"><\/span><span class=\"ez-toc-section\" id=\"Summary_and_Conclusion\"><\/span><span class=\"ez-toc-section\" id=\"Summary_and_Conclusion\"><\/span>Summary and Conclusion<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n<p>O-304 is another approach through AMPK activation but limited research data makes comparison challenging.<\/p>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"References\"><\/span><span class=\"ez-toc-section\" id=\"References\"><\/span><span class=\"ez-toc-section\" id=\"References\"><\/span><span class=\"ez-toc-section\" id=\"References\"><\/span>References<span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><span class=\"ez-toc-section-end\"><\/span><\/h2>\n<ul class=\"wp-block-list\">\n<li>Billon C, et al. <strong>ACS Chem Biol<\/strong>. 2023.<\/li>\n<li><strong>Welch R<\/strong>, <strong>Banerjee S<\/strong>, et al. Preclinical studies of <strong>slu pp 332<\/strong> in <strong>diet induced obesity<\/strong> models.<\/li>\n<li>Xu et al. 2023. <strong>Mitochondrial biogenesis<\/strong> and <strong>exercise mimetic<\/strong> effects of <strong>pp 332<\/strong>.<\/li>\n<li>Clinical trial databases for <strong>exercise mimetics<\/strong> research and safety studies.<\/li>\n<li>Regulatory documents for <strong>experimental therapeutics<\/strong> classification and development pathway for <strong>metabolic<\/strong> interventions. and O-304 Introduction<\/li>\n<\/ul>\n\n<p>SLU-PP-332 works through estrogen-related receptors activation, specifically ERR\u03b1, O-304 through AMPK activation pathways, but O-304 (ATX-304) has progressed further in clinical development than SLU-PP-332, having completed Phase IIa human trials while SLU-PP-332 remains in preclinical research stages.<\/p>\n\n","protected":false},"excerpt":{"rendered":"<p> [\u2026]\n","protected":false},"author":1,"featured_media":617,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-1209","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-research-liquids"],"_links":{"self":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1209","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/comments?post=1209"}],"version-history":[{"count":0,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/posts\/1209\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media\/617"}],"wp:attachment":[{"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/media?parent=1209"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/categories?post=1209"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lotilabs.com\/resources\/wp-json\/wp\/v2\/tags?post=1209"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}